




RealRate

PHARMACEUTICAL 2014

Intra Cellular Therapies Inc
Rank 88 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Intra Cellular Therapies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra Cellular Therapies Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Intra Cellular Therapies Inc is the variable Research and Development, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 293%, being 50% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	38,249
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,834
Liabilities, Non-Current	0
Other Assets	132
Other Compr. Net Income	0
Other Expenses	631
Other Liabilities	0
Other Net Income	30
Other Revenues	2,737
Property and Equipment	68
Research and Development	23,028
Selling, General and Administrative Expense	5,976

Output Variable	Value in 1000 USD
Assets	38,449
Liabilities	6,834
Expenses	29,635
Revenues	2,737
Stockholders Equity	31,615
Net Income	-26,868
Comprehensive Net Income	-26,868
BaseVar	38,842
ECR before Limited Liability	186%
Economic Capital Ratio	293%